Comparative analysis of CRISPR off-target discovery tools following ex vivo editing of CD34+ hematopoietic stem and progenitor cells

Mol Ther. 2023 Apr 5;31(4):1074-1087. doi: 10.1016/j.ymthe.2023.02.011. Epub 2023 Feb 15.

Abstract

While a number of methods exist to investigate CRISPR off-target (OT) editing, few have been compared head-to-head in primary cells after clinically relevant editing processes. Therefore, we compared in silico tools (COSMID, CCTop, and Cas-OFFinder) and empirical methods (CHANGE-Seq, CIRCLE-Seq, DISCOVER-Seq, GUIDE-Seq, and SITE-Seq) after ex vivo hematopoietic stem and progenitor cell (HSPC) editing. We performed editing using 11 different gRNAs complexed with Cas9 protein (high-fidelity [HiFi] or wild-type versions), then performed targeted next-generation sequencing of nominated OT sites identified by in silico and empirical methods. We identified an average of less than one OT site per guide RNA (gRNA) and all OT sites generated using HiFi Cas9 and a 20-nt gRNA were identified by all OT detection methods with the exception of SITE-seq. This resulted in high sensitivity for the majority of OT nomination tools and COSMID, DISCOVER-Seq, and GUIDE-Seq attained the highest positive predictive value (PPV). We found that empirical methods did not identify OT sites that were not also identified by bioinformatic methods. This study supports that refined bioinformatic algorithms could be developed that maintain both high sensitivity and PPV, thereby enabling more efficient identification of potential OT sites without compromising a thorough examination for any given gRNA.

Keywords: CRISPR/Cas9; DNA damage repair; genome editing; genotoxicity; hematopoietic stem cells; next-generation sequencing.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antigens, CD34
  • CRISPR-Associated Protein 9 / genetics
  • CRISPR-Cas Systems*
  • Gene Editing* / methods
  • Hematopoietic Stem Cells / metabolism
  • RNA, Guide, CRISPR-Cas Systems

Substances

  • Antigens, CD34
  • CRISPR-Associated Protein 9
  • RNA, Guide, CRISPR-Cas Systems